NCT06489028View on ClinicalTrials.gov

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

December 26, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

September 30, 2027

Conditions
Venous Leg Ulcer
Interventions
DRUG

allo-APZ2-CVU

Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)

DRUG

Placebo

Placebo

Trial Locations (15)

33012

RHEACELL Clinical Trial Site, Hialeah

33136

RHEACELL Clinical Trial Site, Miami

55455

RHEACELL Clinical Trial Site, Minneapolis

02114

RHEACELL Clinical Trial Site, Boston

Unknown

RHEACELL Clinical Trial Site, Multiple Locations

RHEACELL Clinical Trial Site, Multiple Locations

RHEACELL Clinical Trial Site, Multiple Locations

RHEACELL Clinical Trial Site, Several Locations

RHEACELL Clinical Trial Site, Multiple Locations

RHEACELL Clinical Trial Site, Multiple Locations

RHEACELL Clinical Trial Site, Multiple Locations

RHEACELL Clinical Trial Site, Multiple Locations

RHEACELL Clinical Trial Site, Multiple Locations

RHEACELL Clinical Trial Site, Multiple Locations

RHEACELL Clinical Trial Site, Multiple Locations

Sponsors
All Listed Sponsors
collaborator

FGK Clinical Research GmbH

INDUSTRY

lead

RHEACELL GmbH & Co. KG

INDUSTRY